Elevated serum tumor necrosis factor-alpha concentrations and bioactivity in Type 2 diabetics and patients with android type obesity

G. Winkler, F. Salamon, G. Harmos, D. Salamon, G. Speer, O. Szekeres, P. Hajós, M. Kovács, K. Simon, K. Cseh

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

The role of tumor necrosis factor-alpha in insulin resistance has been studied in 59 patients with Type 2 diabetes, 28 with android type obesity and 35 healthy lean controls. Immunoreactive concentrations and bioactivity of serum tumor necrosis factor-alpha have repeatedly been determined in 8 weeks intervals for 12 months, five times per patients, by using ELISA and L929 cell cytotoxicity bioassay. Significantly higher immunoreactive tumor necrosis factor-alpha concentrations and bioactivity have been found in both, the Type 2 diabetic and obese groups as compared to the healthy persons. Tumor necrosis factor-alpha concentrations and bioactivity have showed a significant positive linear correlation with the elevated basal serum C- peptide levels and body mass indexes in both groups of patients. According to these data the cytokine might play a role in insulin resistance in obesity as well in Type 2 diabetes.

Original languageEnglish
Pages (from-to)169-174
Number of pages6
JournalDiabetes Research and Clinical Practice
Volume42
Issue number3
DOIs
Publication statusPublished - Dec 1 1998

Fingerprint

Tumor Necrosis Factor-alpha
Obesity
Serum
Type 2 Diabetes Mellitus
Insulin Resistance
C-Peptide
Biological Assay
Body Mass Index
Enzyme-Linked Immunosorbent Assay
Cytokines

Keywords

  • C-peptide
  • Insulin resistance
  • Obesity
  • Tumor necrosis factor-alpha
  • Type 2 diabetes

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Elevated serum tumor necrosis factor-alpha concentrations and bioactivity in Type 2 diabetics and patients with android type obesity. / Winkler, G.; Salamon, F.; Harmos, G.; Salamon, D.; Speer, G.; Szekeres, O.; Hajós, P.; Kovács, M.; Simon, K.; Cseh, K.

In: Diabetes Research and Clinical Practice, Vol. 42, No. 3, 01.12.1998, p. 169-174.

Research output: Contribution to journalArticle

@article{be54b758bc4242bf861d5905625f4ca6,
title = "Elevated serum tumor necrosis factor-alpha concentrations and bioactivity in Type 2 diabetics and patients with android type obesity",
abstract = "The role of tumor necrosis factor-alpha in insulin resistance has been studied in 59 patients with Type 2 diabetes, 28 with android type obesity and 35 healthy lean controls. Immunoreactive concentrations and bioactivity of serum tumor necrosis factor-alpha have repeatedly been determined in 8 weeks intervals for 12 months, five times per patients, by using ELISA and L929 cell cytotoxicity bioassay. Significantly higher immunoreactive tumor necrosis factor-alpha concentrations and bioactivity have been found in both, the Type 2 diabetic and obese groups as compared to the healthy persons. Tumor necrosis factor-alpha concentrations and bioactivity have showed a significant positive linear correlation with the elevated basal serum C- peptide levels and body mass indexes in both groups of patients. According to these data the cytokine might play a role in insulin resistance in obesity as well in Type 2 diabetes.",
keywords = "C-peptide, Insulin resistance, Obesity, Tumor necrosis factor-alpha, Type 2 diabetes",
author = "G. Winkler and F. Salamon and G. Harmos and D. Salamon and G. Speer and O. Szekeres and P. Haj{\'o}s and M. Kov{\'a}cs and K. Simon and K. Cseh",
year = "1998",
month = "12",
day = "1",
doi = "10.1016/S0168-8227(98)00109-0",
language = "English",
volume = "42",
pages = "169--174",
journal = "Diabetes Research and Clinical Practice",
issn = "0168-8227",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Elevated serum tumor necrosis factor-alpha concentrations and bioactivity in Type 2 diabetics and patients with android type obesity

AU - Winkler, G.

AU - Salamon, F.

AU - Harmos, G.

AU - Salamon, D.

AU - Speer, G.

AU - Szekeres, O.

AU - Hajós, P.

AU - Kovács, M.

AU - Simon, K.

AU - Cseh, K.

PY - 1998/12/1

Y1 - 1998/12/1

N2 - The role of tumor necrosis factor-alpha in insulin resistance has been studied in 59 patients with Type 2 diabetes, 28 with android type obesity and 35 healthy lean controls. Immunoreactive concentrations and bioactivity of serum tumor necrosis factor-alpha have repeatedly been determined in 8 weeks intervals for 12 months, five times per patients, by using ELISA and L929 cell cytotoxicity bioassay. Significantly higher immunoreactive tumor necrosis factor-alpha concentrations and bioactivity have been found in both, the Type 2 diabetic and obese groups as compared to the healthy persons. Tumor necrosis factor-alpha concentrations and bioactivity have showed a significant positive linear correlation with the elevated basal serum C- peptide levels and body mass indexes in both groups of patients. According to these data the cytokine might play a role in insulin resistance in obesity as well in Type 2 diabetes.

AB - The role of tumor necrosis factor-alpha in insulin resistance has been studied in 59 patients with Type 2 diabetes, 28 with android type obesity and 35 healthy lean controls. Immunoreactive concentrations and bioactivity of serum tumor necrosis factor-alpha have repeatedly been determined in 8 weeks intervals for 12 months, five times per patients, by using ELISA and L929 cell cytotoxicity bioassay. Significantly higher immunoreactive tumor necrosis factor-alpha concentrations and bioactivity have been found in both, the Type 2 diabetic and obese groups as compared to the healthy persons. Tumor necrosis factor-alpha concentrations and bioactivity have showed a significant positive linear correlation with the elevated basal serum C- peptide levels and body mass indexes in both groups of patients. According to these data the cytokine might play a role in insulin resistance in obesity as well in Type 2 diabetes.

KW - C-peptide

KW - Insulin resistance

KW - Obesity

KW - Tumor necrosis factor-alpha

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=0032429844&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032429844&partnerID=8YFLogxK

U2 - 10.1016/S0168-8227(98)00109-0

DO - 10.1016/S0168-8227(98)00109-0

M3 - Article

C2 - 9925347

AN - SCOPUS:0032429844

VL - 42

SP - 169

EP - 174

JO - Diabetes Research and Clinical Practice

JF - Diabetes Research and Clinical Practice

SN - 0168-8227

IS - 3

ER -